Abstract: Methods for identifying and isolating CD8 T cells that produce interleukin-13 upon activation are provided. The present methods leverage one or more newly-identified biomarkers to identify such CD8 T cells and, in certain cases, sort the same. Certain methods comprise obtaining a sample from a mammal, quantifying a level of expression of one or more biomarkers therein, and determining if the level of expression is elevated as compared, wherein an elevated expression level is indicative of an active disease state. Antisera and antibodies are also provided. In particular, an anti-C10orf128 antiserum formulated against a particular peptide is provided, such anti-C10orf128 antiserum characterized in that it identifies a subset of CD8 T cells that produce interleukin-13 upon activation.

Abstract: A previously unknown T cell receptor (TCR) activation pathway dependent on the aryl hydrocarbon receptor conferring resistance to calcineurin inhibitors and mTOR inhibitors is disclosed, including application of this pathway to the diagnosis and treatment of certain disease states refractory to treatment with calcineurin inhibitors. This alternative TCR activation pathway uniquely exists in a subset of CD8 T cells expanded in the setting of chronic rejection or rheumatoid arthritis. Expansion of this newly discovered calcineurin and mTOR inhibitor resistant CD8 T cell subset in humans can be quantified by measuring levels of certain biomarkers in the circulating CD8 T cell pool, such as Pla2g4a, to diagnose disease states mediated thereby. Additionally, methods for diagnosing ongoing active inflammation mediated by this resistant CD8 T cell subset in either chronic rejection or rheumatoid arthritis are provided, which comprise measuring levels of the biomarker Scin in the circulating CD8 T cell pool.

Abstract: Two patients diagnosed with KLS were treated. One patient had severe KLS that progressed to the equivalent of pediatric Kawasaki Disease Shock Syndrome (KDSS). The second patient had a typical KLS presentation and clinical course. Cytokines and chemokines provide inflammatory signatures in the serum that reflect the polarity of the immune response and the affected cell types. Multiplex ELISA technology was used to define the cytokine milieu in the serum of the two adult HIV patients with KLS during the acute and convalescent phases. Those sera were compared with sera from asymptomatic HIV subjects and a normal serum control.

Abstract: Methods for identifying and isolating CD8 T cells that produce interleukin-13 upon activation are provided. The present methods leverage one or more newly-identified biomarkers to identify such CD8 T cells and, in certain cases, sort the same. Certain methods comprise obtaining a sample from a mammal, quantifying a level of expression of one or more biomarkers therein, and determining if the level of expression is elevated as compared, wherein an elevated expression level is indicative of an active disease state. Antisera and antibodies are also provided. In particular, an anti-C10orf128 antiserum formulated against a particular peptide is provided, such anti-C10orf128 antiserum characterized in that it identifies a subset of CD8 T cells that produce interleukin-13 upon activation.

Abstract: Methods are provided for isolating CD8+ T cells. Furthermore, methods for purifying a subset of IL-13 expressing CD8 T cells are provided, such methods comprising the steps of marking the CD8+ T cells by labeling CD8, or selectively removing non-CD8 cells, and then purifying a subset of IL-13 expressing CD8+ T cells by marking a human biomarker such as C10orf128. Related antibodies and antiserums are also described, such antibodies related to a cell surface domain peptide for biomarker C10orf128, and human homologs of related mouse “activated” CD8IL-13 cell surface biomarkers Tm4sf19 and 1830127L07Rik.

Abstract: A previously unknown T cell receptor (TCR) activation pathway dependent on the aryl hydrocarbon receptor conferring resistance to calcineurin inhibitors and mTOR inhibitors is disclosed, including application of this pathway to the diagnosis and treatment of certain disease states refractory to treatment with calcineurin inhibitors. This alternative TCR activation pathway uniquely exists in a subset of CD8 T cells expanded in the setting of chronic rejection or rheumatoid arthritis. Expansion of this newly discovered calcineurin and mTOR inhibitor resistant CD8 T cell subset in humans can be quantified by measuring levels of certain biomarkers in the circulating CD8 T cell pool, such as Pla2g4a, to diagnose disease states mediated thereby. Additionally, methods for diagnosing ongoing active inflammation mediated by this resistant CD8 T cell subset in either chronic rejection or rheumatoid arthritis are provided, which comprise measuring levels of the biomarker Scin in the circulating CD8 T cell pool.

Abstract: MHC class II-restricted Chlamydia-specific CD4 T cell clones recognize infected upper reproductive tract epithelial cells as early as 12 hours post infection. The timing and degree of T cell activation are dependent on the interferon milieu. Different interferons have different effects on T-cell activation; interferon IFN-? blunts IFN-? induced up regulation of epithelial cell surface MHC class II and T cell activation. A subset of CD4 T-cells that was especially good at clearing Chlamydia infections from the genital tracts of infected mice was found to express the genes Casd1 and Plac8. The mouse Casd1 genes shares some 95 percent identity with the human gene. The differential expression of either Plac8 or Casd1 in COD cells in response to an infection of epithelial tissue provides a ready methodology for the identification of individuals exposed to epithelial infections and a tool for developing vaccines against pathogens that infect epithelial tissue.

Abstract: Methods are provided for isolating CD8+ T cells. Furthermore, methods for purifying a subset of IL-13 expressing CD8 T cells are provided, such methods comprising the steps of marking the CD8+ T cells by labeling CD8, or selectively removing non-CD8 cells, and then purifying a subset of IL-13 expressing CD8+ T cells by marking a human biomarker such as C10orf128. Related antibodies and antiserums are also described, such antibodies related to a cell surface domain peptide for biomarker C10orf128, and human homologs of related mouse “activated” CD8IL-13 cell surface biomarkers Tm4sf19 and 1830127L07Rik.

Abstract: Two patients diagnosed with KLS were treated. One patient had severe KLS that progressed to the equivalent of pediatric Kawasaki Disease Shock E Syndrome (KDSS). The second patient had a typical KLS presentation and clinical course. Cytokines and chemokines provide inflammatory signatures in the serum that reflect the polarity of the immune response and the affected cell types. Multiplex ELISA technology was used to define the cytokine milieu in the serum of the two adult IIIV patients with KLS during the acute and convalescent phases. Those sera were compared with sera from asymptomatic HIV subjects and a normal serum control.

Abstract: Isolated, Chlamydia-specific, IL-13 expressing CD8+ T cell clones are provided for understanding the biology of Chlamydia infection and screening of therapeutics. Furthermore, methods are provided for isolating CD8+ T cells comprising the steps of infecting or identifying a naturally infected mammal with at least one species of Chlamydia causing bacteria, allowing the bacteria to clear or for a T cell immune response to the natural infection, collecting immune splenocytes from the mammal, providing at least one antigen from a Chlamydia-specific bacteria, and expanding and depleting the CD4+ T cell population or purifying the CD8 T cell population to isolate IL-13 expressing CD8+ T cell clones.

Abstract: Methods for identifying a subset of CD8 T cells that is resistant to an inhibitor, specifically cyclosporine, rapamycin and/or tacrolimus, by detecting expression levels of human biomarkers are disclosed. The methods include determining whether a subset of certain CD8 T cells expresses elevated levels of Scin and/or Pla2g4a, with an elevated level indicative of proliferation of the identified CD8 T cells. Also disclosed are methods of diagnosing, monitoring and treating rheumatoid arthritis and transplant rejection, including determining and/or monitoring the expansion of a subset of CD8 T cells by measuring the level of expression of a biomarker in the population of the CD8 T cell subset.

Abstract: Utilizing a novel T cell culture system based on allogeneic epithelial antigen presenting cells (semi-professional APC), a cyclosporin-resistant CD8 T cell clone with minimal cytolytic capability was isolated. Derivation of the novel alloantigen-specific CD8 T cell clones involved previous priming with an allogeneic skin graft, implying expansion of this T cell subset during transplant rejection. Characterization and comparison of the cyclosporin and rapamycin-resistant CD 8 T cell clone with typical cyclosporin-sensitive CD 8 T cells suggests that it is a member of a CD8 T cell subset with a unique cell surface phenotype and novel TCR activation pathways, and that these unique CD8 T cell clones reflect the immunobiology of chronic rejection within the non-hematopoetic microenvironments of solid organs and vascular walls. These cells express the aryl-hydrocarbon receptor. T-cells of this type are referred to herein as CD8bm12-1 T-cells.

Abstract: MHC class II-restricted Chlamydia-specific CD4 T cell clones recognize infected upper reproductive tract epithelial cells as early as 12 hours post infection. The timing and degree of T cell activation are dependent on the interferon milieu. Different interferons have different effects on T-cell activation; interferon IFN-? blunts IFN-? induced up regulation of epithelial cell surface MHC class II and T cell activation. A subset of CD4 T-cells that was especially good at clearing Chlamydia infections from the genital tracts of infected mice was found to express the genes Casd1 and Plac8. The mouse Casd1 genes shares some 95 percent identity with the human gene. The differential expression of either Plac8 or Casd1 in COD cells in response to an infection of epithelial tissue provides a ready methodology for the identification of individuals exposed to epithelial infections and a tool for developing vaccines against pathogens that infect epithelial tissue.

Abstract: The present invention is an enclosed display case having slidable trays therein movable from the outside of the display case. The slidable trays are stacked either vertically or horizontally with the items contained thereon being visible through a locked sliding glass door of the display case. Each of the trays has rollers to aid the movement of the trays along grooves inside the display case. Knobs extend from the side of the trays through slots to the outside of the display case to allow movement of the trays by customers to view items contained on each tray. A three-fourths length thin sliding bar moves with each tray to cover the slots in the side of the display case thereby preventing pilferage through the slots by customers.